Document Detail


Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model.
MedLine Citation:
PMID:  19147279     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Germline mutations in LKB1 cause Peutz-Jeghers syndrome (PJS), an autosomal dominant disorder with a predisposition to gastrointestinal polyposis and cancer. Hyperactivation of mTOR-signaling has been associated with PJS. We previously reported that rapamycin treatment of Lkb1(+/-) mice after the onset of polyposis reduced the polyp burden. Here we evaluated the preventive efficacy of rapamycin on Peutz-Jeghers polyposis. We found that rapamycin treatment of Lkb1(+/-) mice initiated before the onset of polyposis in Lkb1(+/-) mice led to a dramatic reduction in both polyp burden and polyp size and this reduction was associated with decreased phosphorylation levels of S6 and 4EBP1. Together, these findings support the use of rapamycin as an option for chemoprevention and treatment of PJS.
Authors:
Chongjuan Wei; Christopher I Amos; Nianxiang Zhang; Jing Zhu; Xiaopei Wang; Marsha L Frazier
Related Documents :
16630169 - Ladd syndrome is caused by fgf10 mutations.
18242159 - A pro253arg mutation in fibroblast growth factor receptor 2 (fgfr2) causes skeleton mal...
20493809 - Phosphatase-dependent and -independent functions of shp2 in neural crest cells underlie...
11861489 - A mouse model of alagille syndrome: notch2 as a genetic modifier of jag1 haploinsuffici...
22217889 - Deadly drop-cholinergic syndrome from wearing a laundered uniform.
1977309 - Definitive localization of x-linked kallman syndrome (hypogonadotropic hypogonadism and...
3560119 - Retinitis pigmentosa and deafness.
24497809 - Von hippel-lindau syndrome: demonstration of entire disease spectrum with (68)ga-dotano...
19089249 - Oral findings in patients with apert syndrome.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2009-01-14
Journal Detail:
Title:  Cancer letters     Volume:  277     ISSN:  1872-7980     ISO Abbreviation:  Cancer Lett.     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-03-30     Completed Date:  2009-05-07     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  149-54     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibiotics, Antineoplastic / therapeutic use*
Carrier Proteins / physiology
Disease Models, Animal
Germ-Line Mutation
Intestinal Polyps / genetics,  pathology,  prevention & control*
Mice
Mice, Knockout
Peutz-Jeghers Syndrome / genetics,  pathology,  prevention & control*
Phosphorylation
Phosphotransferases (Alcohol Group Acceptor) / physiology
Protein-Serine-Threonine Kinases / genetics*
Signal Transduction
Sirolimus / therapeutic use*
TOR Serine-Threonine Kinases
Grant Support
ID/Acronym/Agency:
CA 123603/CA/NCI NIH HHS; CA 16672/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS; P30 CA016672-34S59033/CA/NCI NIH HHS; P30 ES 007784/ES/NIEHS NIH HHS; P30 ES007784-13/ES/NIEHS NIH HHS; P50 CA 70907/CA/NCI NIH HHS; P50 CA070907/CA/NCI NIH HHS; P50 CA070907-09/CA/NCI NIH HHS; P50 CA070907-10/CA/NCI NIH HHS; R03 CA123603-02/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Carrier Proteins; EC 2.7.1.-/Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.-/Stk11 protein, mouse; EC 2.7.1.1/TOR Serine-Threonine Kinases; EC 2.7.1.1/mTOR protein, mouse; EC 2.7.11.1/Protein-Serine-Threonine Kinases; W36ZG6FT64/Sirolimus
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Production of apoptosis-inducing substances from soybean protein by Clostridium butyricum: character...
Next Document:  Selection of metal oxides in the preparation of rice husk ash (RHA)/CaO sorbent for simultaneous SO(...